Addressing Clinical Inertia
in CKD & Heart Failure
Management
Improving Fundamentals
Through Enhanced Knowledge
of CKD & Heart Failure
"Clinicians often stop RAASi therapy in the presence of mild or moderate hyperkalemia. While the potassium may initially come down, you have now exchanged a short- term risk for a long-term risk. Potassium binders are enablers. They enable you to do what you know is right, per guidelines, and give therapy that will help the kidney and the heart improve function."
— George Bakris, MD, and Javed Butler, MD
Steering Committee Co-Chairs
Welcome to Addressing Clinical Inertia in CKD
& Heart Failure Management
This NEW CME series takes a look at the challenges facing healthcare professionals involved in the care of patients with CKD and HF. After learning about the latest guideline recommendations and clinical trial data, participants will be able to translate this advancing knowledge into clinical practice to increase the number of patients with CKD and HF receiving the most appropriate, optimal therapy.
Check out the Featured Programs below and stay tuned for new programs launching this year.
Explore our CME Curriculum on Chronic Kidney Disease & Heart Failure for Guideline-Recommended Treatment Options & Take a Deep Dive Into the Importance of Maintaining RAASi Therapy
VOICES OF THE
STEERING COMMITTEE
FEATURED PROGRAMS
Expert Insights: Managing Patients with CKD, Hyperkalemia,
and Continued RAASi Therapy Through a Case Study Approach
Host: Matthiew Weir, MD
Guests: Gates Colbert, MD, Robert Toto, MD
Potassium Binders Allow Maximal RAASi Therapy:
Helpful Tips for Clinicians
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MPH, MBA
STAY UP
TO DATE
RESOURCES
Explore resources and links for
CKD & HF.
Stay up to date on the latest clinical trial findings
and recommendations for care.
WHO WE ARE
STEERING COMMITTEE
LEADING EXPERTS IN CKD & HEART FAILURE MANAGEMENT
We’ve brought together a group of nationally renowned leaders in CKD and HF to share their robust research and vast clinical experience. Meet our experts and join us in our journey to help improve outcomes in patients with CKD and HF with a focus on hyperkalemia.
MEET THE COMMITTEE
George L. Bakris, MD (Co-Chair)
Javed Butler, MD, MBA, MPH (Co-Chair)
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Gates Colbert, MD
Ileana L. Piña, MD, MPH, FAHA, FACC
Robert Toto, MD
OUR GOAL
ABOUT THIS INITIATIVE
Addressing Clinical Inertia in CKD &
Heart Failure Management
|
This engaging, multimodal initiative—developed in collaboration with 6 nationally renowned leaders in the management of chronic kidney disease and heart failure—provides foundational activities that will drive greater awareness and understanding of the impact of CKD and HF on patient lives. |
|
Together, we will explore the need for more personalized referral, diagnosis, and treatment with the goal of ensuring better outcomes for every patient. |
This engaging, multimodal initiative—developed in collaboration with 6 nationally renowned leaders in the management of chronic kidney disease and heart failure—provides foundational activities that will drive greater awareness and understanding of the impact of CKD and HF on patient lives.
Together, we will explore the need for more personalized referral, diagnosis, and treatment with the goal of ensuring better outcomes for every patient.